+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Stem Cells Market Size, Share & Trends Analysis Report by Product (Adult Stem Cells, HESC), by Application, by Technology, by Therapy, by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4764577
  • Report
  • February 2020
  • Region: Global
  • 190 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • ALDAGEN
  • BioTime, Inc.
  • Celgene Corporation
  • ESI BIO
  • Nuo Therapeutics, Inc.
  • Pluristem
  • MORE
The global stem cells market size is expected to reach USD 17.9 billion by 2027, expanding at a CAGR of 8.2%. Recent advances in tissue engineering strategies hold the potential to draw attention to the treatment of several chronic disorders. Moreover, automation in adult and cord blood processing and storage is expected to drive market growth significantly.

The development of banking facilities and resultant enhancement of stem cell production, storage, and characterization are also expected to enhance the volumetric capabilities of this therapy, globally. This would lead to revenue generation in the global market.

Regenerative medicine and cellular therapies are considered to transform the healthcare industry in a few years. Therefore, key players are focused on developing advanced therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, degenerative eye disorders, cancer, and stroke. Most of these therapies are under clinical trials and are expected to be launched soon.

Furthermore, the presence of a strong, diverse clinical pipeline is expected to accelerate revenue generation in the global market. Easy access to data through genomic, proteomic, and EHR databases has encouraged companies to investigate various therapies to aid in the treatment of previously untreatable conditions.

Further key findings from the report suggest:
  • Adult stem cells (ASCs) segment occupied the largest share of the products in 2019 and is expected to maintain its dominance across the analysis period
  • Factors such as long term renewal property, low rejection rates, and minimal ethical concerns associated with the utility of ASCs are attributive towards larger market share
  • The regenerative medicine segment accounted for the largest share of owing to a huge pipeline for regenerative medicine products
  • The cell acquisition technology segment occupied a major revenue share and is anticipated to witness the fastest CAGR over the forecast period owing to a rise in the number of research projects that require the application of cell harvesting technologies
  • Allogenic therapy is the most commonly adopted therapy owing to its graft-versus-cancer response in cancer treatment and graft-versus-host response in organ or tissue transplant
  • These responses allow allogenic stem cells to kill the cancer remaining after drug therapy and to prevent organ rejection and other complications post-surgery
  • Presence of major companies, extensive government funding, and increasing research have contributed to the largest market share in North America
  • The Asia Pacific region is expected to grow at a lucrative pace owing to strong product pipelines in regenerative therapies and large patient population
  • Osiris Therapeutics Inc, BIOTIME, INC., Celgene Corporation, STEMCELL Technologies Inc., and Cynata are some of the key players operating in the stem cells market.
  • The key players are undertaking strategic initiatives to maintain their market share. They are keen to seek investment from other bodies and also collaborate with other pharmaceutical giants. This is set to enhance market growth over the forecast period.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ALDAGEN
  • BioTime, Inc.
  • Celgene Corporation
  • ESI BIO
  • Nuo Therapeutics, Inc.
  • Pluristem
  • MORE
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 List of Data Sources
1.3 Information or Data Analysis
1.4 Market Formulation & Validation

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Stem Cells Market Variables, Trends & Scope
3.1 Market Segmentation& Scope
3.1.1 Market Driver Analysis
3.1.1.1 Technological advancement involving stem cells therapy
3.1.1.2 Increasing vaccine production
3.1.1.3 Rising demand for regenerative medicines
3.1.1.4 Patent expiration of blockbuster biologics
3.1.1.5 Rising demand for monoclonal antibodies
3.1.1.6 Growing R&D investments in biotechnology sector
3.1.1.7 Development of effective personalized medicine diagnostic & therapeutic procedures
3.1.1.8 Increasing prevalence of cancer
3.1.2 Market Restraint Analysis
3.1.2.1 Ethical concerns related to stem cell research
3.2 Penetration & Growth Prospect Mapping for Stem Cell Product Types, 2019
3.3 Stem Cells Market & Regenerative Medicine Pipeline Analysis
3.3.1 Pfizer Inc.
3.3.2 Abbott (St. Jude Children's Research Hospital)
3.3.3 GlaxoSmithKline plc.
3.3.4 Baxter
3.3.5 Stempeutics Research Pvt Ltd
3.3.6 ReNeuron Group plc
3.3.7 Regen BioPharma, Inc
3.3.8 Promethera Biosciences
3.3.9 U.S. Stem cell Inc.
3.3.10 Astellas Pharma Inc.
3.3.11 Stempeutics Research Pvt. Ltd
3.3.12 Pluristem Therapeutics, Inc. (PSTI)
3.4 Stem Cells - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s

Chapter 4 Stem Cells Market Categorization: Product Estimates & Trend Analysis
4.1 Stem Cells Market: Product Movement Analysis
4.2 Adult stem cells
4.2.1 Global adult stem cells market, 2016 - 2027 (USD Million)
4.2.2 Neuronal stem cells
4.2.2.1 Global neuronal stem cells market, 2016 - 2027 (USD Million)
4.2.3 Hematopoietic stem cells
4.2.3.1 Global hematopoietic stem cells market, 2016 - 2027 (USD Million)
4.2.4 Mesenchymal stem cells
4.2.4.1 Global mesenchymal stem cells market, 2016 - 2027 (USD Million)
4.2.5 Umbilical cord stem cells
4.2.5.1 Global umbilical cord stem cells market, 2016 - 2027 (USD Million)
4.2.6 Dental stem cells
4.2.6.1 Global dental stem cells market, 2016 - 2027 (USD Million)
4.2.7 Adipose‐derived stem cells
4.2.7.1 Global adipose‐derived stem cells market, 2016 - 2027 (USD Million)
4.2.8 Dedifferentiated fat (DFAT) cells
4.2.8.1 Global dedifferentiated fat (DFAT) cells market, 2016 - 2027 (USD Million)
4.2.9 Other adult-derived stem cells
4.2.9.1 Global other adult-derived stem cells market, 2016 - 2027 (USD Million)
4.3 Human embryonic stem cells
4.3.1 Global human embryonic stem cells market, 2016 - 2027 (USD Million)
4.4 IPS cells
4.4.1 Global IPS cells market, 2016 - 2027 (USD Million)
4.5 Very small embryonic like stem cells
4.5.1 Global very small embryonic like stem cells market, 2016 - 2027 (USD Million)

Chapter 5 Stem Cells Market Categorization: Application Estimates & Trend Analysis
5.1 Stem Cells Market: Application Movement Analysis
5.2 Regenerative medicine
5.2.1 Global regenerative medicine market, 2016 - 2027 (USD Million)
5.2.2 Neurology
5.2.2.1 Global neurology-based market, 2016 - 2027 (USD Million)
5.2.3 Orthopedics
5.2.3.1 Global orthopedics market, 2016 - 2027 (USD Million)
5.2.4 Oncology
5.2.4.1 Global oncology-based market, 2016 - 2027 (USD Million)
5.2.5 Hematology stem cells
5.2.5.1 Global hematology stem cells market, 2016 - 2027 (USD Million)
5.2.6 Cardiovascular and myocardial infarction-based
5.2.6.1 Global cardiovascular and myocardial infarction-based market, 2016 - 2027 (USD Million)
5.2.7 Soft tissue injuries
5.2.7.1 Global soft tissue injuries market, 2016 - 2027 (USD Million)
5.2.8 Diabetes
5.2.8.1 Global diabetes market, 2016 - 2027 (USD Million)
5.2.9 Liver disorder
5.2.9.1 Global liver disorder market, 2016 - 2027 (USD Million)
5.2.10 Incontinence
5.2.10.1 Global incontinence market, 2016 - 2027 (USD Million)
5.2.11 Others (Crohn’s Disease, Infertility, Immunodeficiency Disorder, Organ Transplants, Ophthalmic Disorder)
5.2.11.1 Global Others (Crohn’s Disease, Infertility, Immunodeficiency Disorder, Organ Transplants, Ophthalmic Disorder) market, 2016 - 2027 (USD Million)
5.3 Drug discovery & development
5.3.1 Global drug discovery & development market, 2016 - 2027 (USD Million)

Chapter 6 Stem Cells Market Categorization: Technology Estimates & Trend Analysis
6.1 Stem Cells Market: Technology Movement Analysis
6.2 Cell acquisition
6.2.1 Global cell acquisition market, 2016 - 2027 (USD Million)
6.2.2 Bone marrow harvest
6.2.2.1 Global bone marrow harvest market, 2016 - 2027 (USD Million)
6.2.3 Umbilical cord blood
6.2.3.1 Global umbilical cord blood market, 2016 - 2027 (USD Million)
6.2.4 Apheresis
6.2.4.1 Global apheresis market, 2016 - 2027 (USD Million)
6.3 Cell production
6.3.1 Global cell production market, 2016 - 2027 (USD Million)
6.3.2 Therapeutic cloning
6.3.2.1 Global therapeutic cloning market, 2016 - 2027 (USD Million)
6.3.3 In-vitro Fertilization
6.3.3.1 Global In-vitro Fertilization market, 2016 - 2027 (USD Million)
6.3.4 Cell culture
6.3.4.1 Global cell culture market, 2016 - 2027 (USD Million)
6.3.5 Isolation
6.3.5.1 Global isolation market, 2016 - 2027 (USD Million)
6.4 Cryopreservation
6.4.1 Global cryopreservation market, 2016 - 2027 (USD Million)
6.5 Expansion and sub-culture
6.5.1 Global expansion and sub-culture market, 2016 - 2027 (USD Million)

Chapter 7 Stem Cells Market Categorization: Stem Cell Therapy Estimates & Trend Analysis
7.1 Stem Cells Market: Stem Cells Therapy Movement Analysis
7.2 Autologous Stem Cell Therapy
7.2.1 Global autologous stem cell therapy market, 2016 - 2027 (USD Million)
7.3 Allogenic Stem Cell Therapy
7.3.1 Global allogenic stem cell therapy market, 2016 - 2027 (USD Million)

Chapter 8 Stem Cells Market Categorization: Regional Estimates & Trend Analysis, by Service Type, Sector, & Application
8.1 Stem cells market share by region, 2019 & 2027
8.2 North America
8.2.1 North America stem cells market, 2016 - 2027 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. stem cell market, by product 2016 - 2027 (USD Million)
8.2.2.2 U.S. stem cell market, by application 2016 - 2027 (USD Million)
8.2.2.3 U.S. stem cell market, by technology 2016 - 2027 (USD Million)
8.2.2.4 U.S. stem cell market, by therapy 2016 - 2027 (USD Million)
8.2.3 Canada
8.2.3.1 Canada stem cell market, by product 2016 - 2027 (USD Million)
8.2.3.2 Canada stem cell market, by application 2016 - 2027 (USD Million)
8.2.3.3 Canada stem cell market, by technology 2016 - 2027 (USD Million)
8.2.3.4 Canada stem cell market, by therapy 2016 - 2027 (USD Million)
8.3 Europe
8.3.1 Europe stem cells market, 2016 - 2027 (USD Million)
8.3.2 Germany
8.3.2.1 Germany stem cell market, by product 2016 - 2027 (USD Million)
8.3.2.2 Germany stem cell market, by application 2016 - 2027 (USD Million)
8.3.2.3 Germany stem cell market, by technology 2016 - 2027 (USD Million)
8.3.2.4 Germany stem cell market, by therapy 2016 - 2027 (USD Million)
8.3.3 U.K.
8.3.3.1 U.K. stem cell market, by product 2016 - 2027 (USD Million)
8.3.3.2 U.K. stem cell market, by application 2016 - 2027 (USD Million)
8.3.3.3 U.K. stem cell market, by technology 2016 - 2027 (USD Million)
8.3.3.4 U.K. stem cell market, by therapy 2016 - 2027 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific stem cells market, 2016 - 2027 (USD Million)
8.4.2 Japan
8.4.2.1 Japan stem cell market, by product 2016 - 2027 (USD Million)
8.4.2.2 Japan stem cell market, by application 2016 - 2027 (USD Million)
8.4.2.3 Japan stem cell market, by technology 2016 - 2027 (USD Million)
8.4.2.4 Japan stem cell market, by therapy 2016 - 2027 (USD Million)
8.4.3 China
8.4.3.1 China stem cell market, by product 2016 - 2027 (USD Million)
8.4.3.2 China stem cell market, by application 2016 - 2027 (USD Million)
8.4.3.3 China stem cell market, by technology 2016 - 2027 (USD Million)
8.4.3.4 China stem cell market, by therapy 2016 - 2027 (USD Million)
8.5 Latin America
8.5.1 Latin America stem cells market, 2016 - 2027 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil stem cell market, by product 2016 - 2027 (USD Million)
8.5.2.2 Brazil stem cell market, by application 2016 - 2027 (USD Million)
8.5.2.3 Brazil stem cell market, by technology 2016 - 2027 (USD Million)
8.5.2.4 Brazil stem cell market, by therapy 2016 - 2027 (USD Million)
8.6 Middle East & Africa
8.6.1 Middle East & Africa stem cells market, 2016 - 2027 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa stem cell market, by product 2016 - 2027 (USD Million)
8.6.2.2 South Africa stem cell market, by application 2016 - 2027 (USD Million)
8.6.2.3 South Africa stem cell market, by technology 2016 - 2027 (USD Million)
8.6.2.4 South Africa stem cell market, by therapy 2016 - 2027 (USD Million)

Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participant Categorization
9.3 Company Profiles
9.3.1 Celgene Corporation
9.3.1.1 Company overview
9.3.1.2 Financial performance
9.3.1.3 Product benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 ReNeuron Group plc
9.3.2.1 Company overview
9.3.2.2 Financial performance
9.3.2.3 Product benchmarking
9.3.2.4 Strategic initiatives
9.3.3 Virgin Health Bank
9.3.3.1 Company overview
9.3.3.2 Financial performance
9.3.3.3 Product benchmarking
9.3.3.4 Strategic initiatives
9.3.4 BIOVAULT FAMILY
9.3.4.1 Company overview
9.3.4.2 Financial performance
9.3.4.3 Product benchmarking
9.3.4.4 Strategic initiatives
9.3.5 Precious Cells International Ltd
9.3.5.1 Company overview
9.3.5.2 Financial performance
9.3.5.3 Product benchmarking
9.3.5.4 Strategic initiatives
9.3.6 Mesoblast Ltd
9.3.6.1 Company overview
9.3.6.2 Financial performance
9.3.6.3 Product benchmarking
9.3.6.4 Strategic initiatives
9.3.7 Caladrius
9.3.7.1 Company overview
9.3.7.2 Financial performance
9.3.7.3 Product benchmarking
9.3.7.4 Strategic initiatives
9.3.8 Neuralstem, Inc.
9.3.8.1 Company overview
9.3.8.2 Financial performance
9.3.8.3 Product benchmarking
9.3.8.4 Strategic initiatives
9.3.9 Opexa Therapeutics, Inc.
9.3.9.1 Company overview
9.3.9.2 Financial performance
9.3.9.3 Product benchmarking
9.3.9.4 Strategic initiatives
9.3.10 Pluristem
9.3.10.1 Company overview
9.3.10.2 Financial performance
9.3.10.3 Product benchmarking
9.3.10.4 Strategic initiatives
9.3.11 STEMCELL Technologies Inc.
9.3.11.1 Company overview
9.3.11.2 Financial performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Cesca Therapeutics, Inc.
9.3.12.1 Company overview
9.3.12.2 Financial performance
9.3.12.3 Product benchmarking
9.3.12.4 Strategic initiatives
9.3.13 Astellas Pharma, Inc.
9.3.13.1 Company overview
9.3.13.1.1 Ocata Therapeutics, Inc.
9.3.13.2 Financial performance
9.3.13.2.1 Financial performance
9.3.13.3 Product benchmarking
9.3.13.4 Strategic initiatives
9.3.14 Cellular Engineering Technologies
9.3.14.1 Company overview
9.3.14.2 Financial performance
9.3.14.3 Product benchmarking
9.3.14.4 Strategic initiatives
9.3.15 BioTime, Inc.
9.3.15.1 Company overview
9.3.15.1.1 Cell Cure Neurosciences LTD.
9.3.15.1.2 ESI BIO
9.3.15.2 Financial performance
9.3.15.3 Product benchmarking
9.3.15.4 Strategic initiatives
9.3.16 BrainStorm Cell Therapeutics
9.3.16.1 Company overview
9.3.16.2 Financial performance
9.3.16.3 Product benchmarking
9.3.16.4 Strategic initiatives
9.3.17 Vericel Corporation
9.3.17.1 Company overview
9.3.17.2 Financial performance
9.3.17.3 Product benchmarking
9.3.17.4 Strategic initiatives
9.3.18 Nuo Therapeutics, Inc.
9.3.18.1 Company overview
9.3.18.1.1 ALDAGEN
9.3.18.2 Financial performance
9.3.18.3 Product benchmarking
9.3.18.4 Strategic initiatives
9.3.19 U.S Stem Cell, Inc.
9.3.19.1 Company overview
9.3.19.2 Financial performance
9.3.19.3 Product benchmarking
9.3.19.4 Strategic initiatives
9.3.20 Athersys, Inc.
9.3.20.1 Company overview
9.3.20.2 Financial performance
9.3.20.3 Product benchmarking
9.3.20.4 Strategic initiatives
9.3.21 Cytori Therapeutics, Inc.
9.3.21.1 Company overview
9.3.21.2 Financial performance
9.3.21.3 Product benchmarking
9.3.21.4 Strategic initiatives
9.3.22 Cryo-Cell International Inc.
9.3.22.1 Company overview
9.3.22.2 Financial performance
9.3.22.3 Product benchmarking
9.3.22.4 Strategic initiatives


*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Celgene Corporation
  • ReNeuron Group plc
  • Virgin Health Bank
  • BIOVAULT FAMILY
  • Precious Cells International Ltd
  • Mesoblast Ltd
  • Caladrius
  • Neuralstem, Inc.
  • Opexa Therapeutics, Inc.
  • Pluristem
  • STEMCELL Technologies Inc.
  • Cesca Therapeutics, Inc.
  • Astellas Pharma, Inc.
  • Ocata Therapeutics, Inc.
  • Cellular Engineering Technologies
  • BioTime, Inc.
  • Cell Cure Neurosciences LTD.
  • ESI BIO
  • BrainStorm Cell Therapeutics
  • Vericel Corporation
  • Nuo Therapeutics, Inc.
  • ALDAGEN
  • U.S Stem Cell, Inc.
  • Athersys, Inc.
  • Cytori Therapeutics, Inc.
  • Cryo-Cell International Inc.
Note: Product cover images may vary from those shown
Adroll
adroll